Heather D. Turner
CEO & DirectorMs. Heather D. Turner, J. D., Esq., is Chief Executive Officer and Director of LB Pharmaceuticals Inc from November 2024. She has been Independent Chairman of Avalyn Pharma Inc. since October 2024. She was Independent Director of Terns Pharmaceuticals, Inc. from November 18, 2024 until May 4, 2026. Ms. Turner has served as Chief Executive Officer of LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company since November 2024. Ms. Turner was President, Chief Executive Officer and Director at Carmot Therapeutics, Inc. since January 2023 to June 2024 and was its Chief Operating Officer from September 2022 to December 2022. She joined Carmot Therapeutics, Inc. in September, 2022. Ms. Turner served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. from April 2019 to May 2022. She was General Counsel at Lyell Immunopharma, Inc. since April 2019 until December 2019. During her time with Lyell, she oversaw the execution of the Company’s IPO readiness process as well as the execution of the Company’s fourth large Nasdaq IPO. Ms. Turner served as Senior Vice President, Executive Vice President, Secretary and General Counsel of Sangamo Therapeutics, Inc. since February 12, 2018 until March 15, 2019, where she oversaw the acquisition and integration of a publicly-traded French company, the legal, compliance and human resources functions and the Company’s international expansion to Europe. and served as Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy at Atara Biotherapeutics, Inc. (Nasdaq: ATRA), or Atara, a publicly-traded allogeneic cell therapy company, from September 2016 to February 2018 and as Vice President and General Counsel of Atara from June 2015 to September 2016. Prior to that, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a company focused on metabolic diseases, from June 2007 to June 2015 and as its Senior Vice President from May 2010 to June 2015, where she led various G&A functions including legal, human resources, risk management, compliance and facilities. She served as Vice President of Orexigen Therapeutics, Inc. She has an extensive experience involving public reporting, compliance and disclosure issues, as well as broad knowledge and experience in negotiating and structuring commercial relationships including distribution, manufacturing, supply and clinical trial agreements. Prior thereto, Ms. Turner worked first as Corporate Counsel and as Associate General Counsel at Conor Medsystems, LLC from July 2005 to June 2007. She served as an Associate General Counsel of Corporate at Conor Medsystems, LLC (formerly, Conor Medsystems, Inc.). Prior to her work at Conor Medsystems, she served as an Associate in the corporate securities group of Cooley Godward Kronish LLP (formerly, Cooley Godward LLP) from 1999 to 2005, where she advised public and private companies, Investors and Board members. Throughout her career, Ms. Turner has advised public and private life science companies on matters ranging from public reporting, public offerings, securities law compliance, mergers and acquisitions, commercial, manufacturing and development contracts, corporate governance, Board duties and other general corporate matters. Ms. Turner is a Member of the State Bar of California. Ms. Turner holds a BA in Environmental Studies from U. C. Santa Barbara and a Juris Doctor degree from University of California Los Angeles School of Law.
Positions
- Company NameLB Pharmaceuticals IncStock CodeLBRXPositionCEO & DirectorColleagues
- HDHeather D. TurnerCEO & Director
- SGScott GarlandIndependent Chairman of the Board
- GSGad SofferChief Operating & Business Officer
- JMJoseph M. MillerChief Financial Officer
- MPMinako PazderaGeneral Counsel
- LBLindsay BeaupreSenior VP of People & Culture
- RMRebecca M. LuseIndependent Director
- JMJohn M. KaneChairman of Scientific Advisory Board
- RHRekha HemrajaniIndependent Director
- Company NameAvalyn Pharma Inc.Stock CodeAVLNPositionIndependent ChairmanColleagues
- LBLyn BaranowskiCEO, President & Director
- DRDouglas R. CarlsonCFO & Chief Business Officer
- MRMelissa RhodesChief Operating Officer
- HMHoward M. LazarusChief Medical Officer
- CSCassie SaitowSenior Director of IR & Corporate Communications
- JCJill CarrollIndependent Director
- EMErin M. LavelleIndependent Director
- KHKathryn HavilandIndependent Director
